Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | GABBR2 | O75899 | 6/20 | 0.44 |
| ▸ | GABBR1 | Q9UBS5 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6278627 | 0.86 | GABBR2 (0.56) | ADRB2ADRA2AADRA2BADRA2CTSHR | |
| SCHEMBL19987462 | 0.86 | ESR1 (0.44) | ADRB2TSHRMAPK1HIF1ATDP1 | |
| SCHEMBL27754040 | 0.86 | ADRB2 (0.41) | ADRB2ADRA2AADRA2BADRA2CTSHR | |
| SCHEMBL24597837 | 0.86 | ESR1 (0.44) | ADRB2TSHRMAPK1HIF1ATDP1 | |
| SCHEMBL19803301 | 0.86 | GABBR2 (0.56) | ADRB2ADRA2AADRA2BADRA2CTSHR | |
| SCHEMBL24597751 | 0.86 | ESR1 (0.44) | ADRB2TSHRMAPK1HIF1ATDP1 | |
| SCHEMBL11225092 | 0.86 | GABBR2 (0.43) | ADRB2ADRA2AADRA2BADRA2CHDAC8 | |
| SCHEMBL19803214 | 0.86 | GABBR2 (0.56) | ADRB2ADRA2AADRA2BADRA2CTSHR | |
| SCHEMBL823013 | 0.84 | HDAC8 (0.56) | HDAC8HDAC6TSHRMAPK1GABBR2 | |
| SCHEMBL20083457 | 0.83 | NR1I2 (0.50) | ADRB2TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| US-20230140941-A1 | NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2023-05-11 | — | — | US | disclosed |
| WO-2022144920-A1 | ATOVAQUONE PRODRUGS | IPCA LABORATORIES LIMITED (IN) | 2022-07-07 | — | — | WO | disclosed |
| US-11274094-B2 | Substituted benzenecarboxamides as IL-17A modulators | DICE ALPHA, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-11078171-B2 | Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-08-03 | — | — | US | disclosed |
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2021-07-08 | — | — | US | disclosed |
| US-20210122757-A1 | SPIROCYCLIC COMPOUNDS AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2021-04-29 | — | — | US | disclosed |
| US-10946018-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES GMBH (CH) | 2021-03-16 | — | — | US | disclosed |
| US-20200331874-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-10-22 | — | — | US | disclosed |
| US-20200237760-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ROIVANT SCIENCES GMBH (CH) | 2020-07-30 | — | — | US | disclosed |
| US-8048903-B2 | 5-iodotetrazoles | LANXESS DEUTSCHLAND GMBH (DE) | 2011-11-01 | — | — | US | disclosed |
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
| US-7803804-B2 | Substituted pyrazines for use in the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2010-09-28 | — | — | US | disclosed |
| US-7803804-B2 | Substituted pyrazines for use in the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2010-09-28 | — | — | US | disclosed |
| US-20090036506-A1 | 5-Iodotetrazoles | LANXESS DEUTSCHLAND GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| US-20090036506-A1 | 5-Iodotetrazoles | LANXESS DEUTSCHLAND GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| US-20080312217-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| US-20080312217-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| EP-1773125-B1 | 5-IODOTETRAZOLES | LANXESS DEUTSCHLAND GMBH (DE) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007064914-A2 | 5-(ARYLSULFONYL)-PYRAZOLOPIPERIDINES | ELAN PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122757-A1 | SPIROCYCLIC COMPOUNDS AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, TPH1 | ADRB2 73/4885ADRA2A 105/4885ADRA2B 277/4885 |
| US-20230140941-A1 | NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPK4 | ADRB2 3842/4885ADRA2A 2942/4885ADRA2B 3334/4885 |
| US-11078171-B2 | Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors | MAPK1, MAPK8, MAPK4 | ADRB2 3462/4885ADRA2A 3545/4885ADRA2B 3485/4885 |
| US-20200237760-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | ADRB2 393/4885ADRA2A 324/4885ADRA2B 459/4885 |
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | ADRB2 393/4885ADRA2A 324/4885ADRA2B 459/4885 |
| US-11274094-B2 | Substituted benzenecarboxamides as IL-17A modulators | IL17A, IL23R, IL18 | ADRB2 1742/4885ADRA2A 2652/4885ADRA2B 1573/4885 |
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, TRPA1 | ADRB2 2128/4885ADRA2A 1812/4885ADRA2B 2385/4885 |
| US-20090036506-A1 | 5-Iodotetrazoles | GPX4, CYP1A1, CYP2E1 | ADRB2 1518/4885ADRA2A 2260/4885ADRA2B 2286/4885 |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | ADRB2 393/4885ADRA2A 324/4885ADRA2B 459/4885 |
| US-20080312217-A1 | Organic Compounds | TRPA1, TRPV1, CHRM1 | ADRB2 69/4885ADRA2A 58/4885ADRA2B 121/4885 |
| US-20200331874-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPK4 | ADRB2 3462/4885ADRA2A 3545/4885ADRA2B 3485/4885 |
| US-10946018-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | ADRB2 393/4885ADRA2A 324/4885ADRA2B 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.